Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
August 6, 2026
Earnings Call Speaker Segments
Larry Keusch
executiveHello, everyone, and thanks for joining the Teleflex Incorporated Second Quarter 2026 Earnings Conference Call this morning. You can find the press release and the slides that go with this call on our site, teleflex.com. Just a note that a replay is going to be accessible on our website. If you'd like to listen to that replay, please see this morning's press release, which has the details. On the line with us today are Jason Weidman, President and Chief Executive Officer, along with John Deren, Executive Vice President and Chief Financial Officer. Jason and John are going to give prepared remarks, and after that, we'll take your questions in the Q&A session. Before we get started, I want to note that certain topics we'll discuss during this conference call will include forward-looking statements about future events, as described in the slides posted in the Investor Relations section of the Teleflex website. Please be aware that these statements are indeed forward-looking by nature and carry risks and uncertainties, so actual events or results could differ materially. Among the factors that might lead actual results or events to differ materially are those referenced in today's press release and in our SEC filings, including our Form 10-K, which is accessible on our website; with that, I'll hand things over to Jason for his remarks.
Jason Weidman
executiveThanks, Larry, and good morning to all of you. I want to start off by noting that my first stretch here at Teleflex has gotten off to an excellent beginning. During these 2 months, my attention has been squarely on getting to know the business, the products, and the organization. That has involved a lot of travel to numerous sites worldwide, sitting down with team members throughout the company, spending time with customers and physicians, and going through the portfolio, the operational priorities, and the opportunities for long-term growth. Even though I'm still new, a few things jumped out at me right away. Our people are outstanding. They're committed. There's genuine pride and confidence in the work we do for patients, and they're keen to build on what we've achieved and push execution forward. The second thing is how solid Teleflex's underlying businesses are — we have excellent products holding market-leading positions across many key categories, powerful brands, and a significant commercial presence around the world. Everything I've seen up to this point has made me even more confident that Teleflex has substantial opportunities ahead, and that the base we've built is the correct one for capturing that potential. Our attention remains fixed on executing the major initiatives already underway: completing the divestitures we've made public, deploying the resulting funds toward the debt paydown and buyback commitments we've made, and tackling the stranded costs associated with those divestitures. Taken as a whole, these steps will produce a more concentrated portfolio, increase our presence in core critical care and high acuity hospital markets, and further reinforce Teleflex's financial and strategic flexibility as the company moves into its next stage of growth. The moves we've made to sell off certain assets, along with how we're directing our capital, show we're being intentional and forward-looking about generating worth. That said, getting where we ultimately want to be will require ongoing, focused effort and steady follow-through across the entire organization. In stepping into this position, the thing I care about most is taking a hard look at how the business operates and then building out both a strategic and an operational roadmap. That roadmap will steer our investment toward where the greatest prospects lie — whether that's durable expansion, new ideas, or squeezing more efficiency out of what we already do — and everything we do is aimed at driving the highest possible return for those who hold our stock. That review hasn't wrapped up yet, and like most companies in medical devices, we'll be concentrating on running the business tightly and dependably from top to bottom, accelerating expansion in the platforms powered by innovation, and ensuring the way we put capital to work remains both careful and well-proportioned. I can't wait to partner with the leadership group and all of our people to keep building on the solid base that's already there, and to continue pushing Teleflex further along in becoming a more concentrated medical technologies leader delivering lasting growth over the long run; at this point I want to turn to what stood out in the second quarter. On a pro forma adjusted constant currency basis, we grew 4.7% overall, while adjusted operating margin reached 19.6%. Our revenue, adjusted margin, and adjusted EPS all came in above what we had anticipated, and the Vascular and Surgical segments in particular delivered very strong results. Meanwhile, Interventional fell short of our projections, because the integration tied to the BI acquisition is moving more slowly than we had anticipated. John will walk you through the details, but we have lowered our revenue outlook for the full year to reflect a more measured view of Interventional growth, while leaving our adjusted operating margin outlook unchanged and lifting our adjusted EPS guidance. We have noted previously that 2026 will be a transitional year for Teleflex as we become a stronger, more focused company. On that note, I can share some good news: we're making solid progress with our strategic overhaul and our commitment to delivering the greatest possible value to shareholders. In December of 2025, we told you about deals we'd reached to divest the Acute Care, Interventional Urology, and OEM businesses, which fit within the broader transformation effort. Earlier this week, we confirmed that the OEM sale has now officially wrapped up, bringing in roughly $1.5 billion, with after-tax proceeds estimated at $1.25 billion. That OEM divestiture, being strategic in nature, accounts for most of the money we expect from the divestitures we've planned, and it will provide funding for paying down debt as well as buying back shares. In a few minutes, John will walk through additional specifics regarding how we plan to use the money from the OEM closing, along with our approach to capital allocation. Now, regarding the sale of Acute Care and Interventional Urology, our confidence that this deal will close has not wavered. Back in March, as we shared before, the FTC sent a second request asking for more information as part of its evaluation of the transaction. We and the other party are cooperating fully with the FTC. Right now, we expect this strategic divestiture to wrap up during the fourth quarter of 2026, though the exact timing hinges on the regulatory review process and the other remaining steps needed to get the deal done. For me, as I concentrate on sustainable growth going forward, pushing innovation forward sits high on Teleflex's list of priorities. The new product possibilities we're working on have me energized, and we've intentionally ramped up what we spend on R&D across the last few quarters — it came to 7.9% of sales during the first half of 2026. Going forward, our priority is putting capital to work wisely on fresh R&D chances that strengthen what we already sell, make use of our call points, and add to our growth story over the long run. On top of that, we've recently seen some genuinely exciting innovation progress, among them the FDA's BLA approval in late July for EZPlas freeze-dried plasma, plus hitting key clinical trial milestones for Freesolve, our novel drug-eluting resorbable magnesium scaffold. Within our Vascular division, EZPlas is set to broaden the emergency medicine offerings. It provides an innovative way to deliver plasma to severely injured patients in combat zones and prehospital environments. It has received approval for treating adults who have uncontrolled bleeding from traumatic injuries, in cases where plasma is needed but other plasma products can't be accessed. EZPlaz holds the distinction of being the initial freeze-dried plasma to receive FDA licensure. The product incorporates a cutting-edge, pliable plastic bag design that allows for rapid and effective reconstitution of freeze-dried plasma. By making plasma transfusion possible in urgent situations where it's essential, it addresses a gap that hadn't been filled. This includes situations like combat zones, as well as helicopters and ground vehicles used for medical transport, since getting traditional plasma goods to those locations is hindered by supply chain and practical difficulties. Now let's look ahead to what's coming for the Interventional division. We remain committed to increasing our investment in research and development for advanced technologies, which means continuing to advance our clinical trials involving Freesolve — an innovative resorbable magnesium scaffold that releases medication and sets itself apart from other options. Freesolve offers short-term structural support while simultaneously administering drugs, working toward an objective that interventional cardiology has long strived for, and it's positioned to support the rapidly expanding movement in coronary and endovascular care toward therapies that leave nothing behind. During the second quarter, we shared several achievements related to the Freesolve clinical program. In May, at the Paris course of revascularization, we presented 4-year follow-up data from the single-arm BIOMAG-1 study. Those results demonstrated that Freesolve maintains its performance over the long term, with a long-term safety profile that remains favorable. We also announced that enrollment for BIOMAG-2 had wrapped up sooner than planned. That trial is the first randomized controlled trial of Freesolve run outside of the United States, and it positions us to report data in late 2027. Finally, we launched the BIOMAG-3 randomized pivotal trial in the U.S., and the initial patient procedures were completed in June at the MedStar Washington Hospital Center. Although this comprehensive clinical program remains in its early phases, the data so far encourage us, and we are excited about the optionality Freesolve gives us going forward.
Jason Weidman
executiveBringing it all together, if you consider these developments and moves as a whole, what they demonstrate is a portfolio with sharper focus, disciplined deployment of capital, and forward momentum in innovation. It's our belief that as a result, Teleflex is positioned to deliver improved execution and better results over the long haul; we are establishing a distinct financial profile that drives value creation through enhanced adjusted margins, lower interest expense, and increased adjusted earnings per share down the road. As far as the company is concerned, 2026 remains a year of transition, and our transformation is already progressing substantially, with concrete milestones being achieved, including the closing of the OEM strategic divestiture and returning capital to shareholders. We expect that sticking with our current priorities will lead to a significant improvement in how we perform financially starting in 2027 and continuing afterward. Moving on, we'll now go over the specifics of our second quarter results from continuing operations, along with the revised financial outlook for 2026. Any growth figures I cite reflect pro forma adjusted constant currency comparisons to the prior year, except where I say otherwise. For 2026, our pro forma adjusted constant currency growth figure leaves out several things: foreign exchange effects, the $9 million Italian payback measure that was recorded in the second half of 2025, and roughly $14 million in continuing operations product revenue that was discontinued at the end of 2025 as part of a strategic realignment. It does, however, factor in a full prior-year period of revenue from the acquired Vascular Intervention business. Everything I'm about to say concerns continuing operations for the second quarter of 2026. In that quarter, Teleflex revenues reached $570.3 million, which represents a 28.9% increase year-over-year on a GAAP basis and a 4.7% increase on a pro forma adjusted constant currency basis. During the quarter, results on the top line showed solid execution across our Vascular and Surgical segments, though this was partly offset by how our Interventional business performed, since it faced impacts from integration and restructuring work tied to the VI business. For the second quarter, adjusted earnings per share came in at $1.76, which is up 1.7% compared with the same period last year and above what we had anticipated; let's now examine our second quarter revenue results more closely. I'll start by going through our revenues by global product category for Q2. First, Vascular. That revenue reached $246.3 million, marking an 8% rise versus a year ago, mainly fueled by gains in our hemostatic products as well as our central access portfolio. Turning to our Surgical segment, we generated $112.1 million in revenue, up 9.2%, with the main drivers being ligation clips, our instrument portfolio and skin safely. Now on to Interventional, where revenue came in at $211.9 million, down 1%. A number of categories did better than the rest, among them hemostatic products, right heart catheters, intraosseous and complex catheters, yet growth for the quarter landed below what we had expected, which mirrors integration and restructuring work still underway related to the VI acquisition. We had always viewed 2026 as a transition year, but integration during the quarter moved more slowly than we anticipated, and that reflects a handful of transition factors we believe will prove temporary. Mitigation actions are moving forward as we work to address the main causes behind these temporary impacts. We still have strong confidence in what this business can achieve strategically and financially over the long run. That said, the original plan had the integration largely wrapped up near the middle of 2026, but we think it's wise to move the finish line for full integration to the back half of 2026, since some transition issues continue to weigh on the business. I've spent two decades working in the Interventional space over the course of my career, and that experience leaves me truly optimistic about Teleflex's future. In general terms, the legacy Teleflex Interventional business fits together very well with the Vascular Intervention business we acquired, since their product offerings and geographic strengths complement one another in a powerful way. In my view, these assets are the right ones for Teleflex to grow its presence in Interventional coronary and peripheral procedures. Going a little deeper, we have excellent products. a wide-ranging portfolio that includes specialty devices physicians depend on and value. I see substantial chances to pick up share, grow geographically and launch new products, including via our innovation pipeline, which offers differentiated products such as Freesolve. While we actively navigate the 2026 transition year, I'm concentrating on setting the business up to succeed in 2027 and beyond. My wider review continues, but my near-term priorities are unambiguous: finish the integration tied to the VI acquisition and put Teleflex in position for better growth as we carry on the broader transformation of our business. That wraps up what I have to say about the second quarter revenue performance. At this point I'd like to hand the call to John for a more detailed look at our financial results. John?
John Deren
executiveThanks, Jason, and good morning. Every result I discuss will relate to continuing operations for 2026. Because discontinued operations have been reclassified, the historical continuing operations figures show the effect of stranded costs across all periods presented. Since Jason already covered revenue, I'll start with margins. Adjusted gross margin for the second quarter of 2026 came in at 61.7%, and the 280 basis point decline from a year earlier was mainly driven by the unfavorable effect of tariffs along with the addition of the Vascular Intervention business, whose gross margin is somewhat below the company average. Notably, no IIFA tariff refunds were recognized during the second quarter. Adjusted operating margin for the second quarter of 2026 was 19.6%, and the 520 basis point drop reflects gross margin pressure versus last year plus greater operating expenses tied to the acquired Vascular Intervention business, as well as more spending on R&D. Adjusted net interest expense came to $26.5 million in the second quarter, compared with $20.3 million a year earlier. That year-over-year rise stems largely from borrowings taken on to fund the Vascular Intervention acquisition and some of the open market share repurchases made in the second quarter of 2026, partly offset by lower interest rates. Our adjusted tax rate for the second quarter of 2026 was 9.9%, versus 14.1% a year earlier. This year-over-year decline is mostly attributable to beneficial tax provisions contained in the One Big Beautiful Bill Act, greater use of U.S. tax credits, and a favorable jurisdictional mix during the quarter. On the bottom line, adjusted earnings per share for the second quarter was $1.76, an increase of 1.7% year-over-year. That gain was primarily the result of a lower share count and tax rate and, to a lesser degree, higher adjusted operating income, partly offset by tariffs and greater interest expense. As of the close of the second quarter, our balance of cash and cash equivalents and restricted cash equivalents stood at $316.9 million, compared with $402.7 million at the end of 2025. Net leverage finished the quarter at roughly 2.8x, a slight increase over the first quarter, driven mainly by borrowings used to fund the share repurchases completed in the second quarter. Pro forma net leverage for the OEM strategic divestiture was approximately 1.9x. Now to our capital allocation strategy. We continue to be committed to returning cash to shareholders through our previously announced $1 billion share repurchase authorization, while also paying down $800 million of debt. To speed up that return of capital to shareholders, during the second quarter we bought back approximately 1.9 million shares of our common stock for $250 million via open market transactions, at an average price of $130.85 per share. With the OEM strategic divestiture now closed, I'm happy to announce that we plan to begin an additional $250 million accelerated share repurchase on August 7. The net proceeds that remain from the OEM strategic divestiture are mainly being used to retire the $700 million Term Loan A-2 connected to the acquisition of the Vascular Intervention business. Also, the money we used for the $250 million share buyback finished in the second quarter will be replaced. Now, on to how we're framing financial guidance. We've said before that 2026 results carry several temporary items tied to our strategic divestitures, and those will affect near-term results, though we expect the close of both deals to soften that impact. So we see 2027 as better reflecting the underlying business, eventually giving a clearer financial picture with meaningful gains in adjusted margins, interest expense and adjusted earnings per share. We've already announced a multiyear restructuring plan too, and it should deliver roughly $50 million in yearly pretax cost savings once finished in mid-2028. Those restructuring actions started in the first quarter of 2026 and are on track, and our guidance still assumes the savings from them pick up speed in the second half of the year. We're also finding more chances to cut costs and staying focused on offsetting the stranded costs tied to the strategic divestitures. With that backdrop, I'll go through the items that will shape our 2026 results. First, our 2026 assumptions still capture the effect of stranded costs, partly offset by TS agreements linked to the recent close of the OEM strategic divestiture. Notably, the TS and MS agreements tied to the Acute Care and Interventional Urology strategic divestitures are broader than those for OEM, since the buyer needs more support, and that will fuel adjusted margin expansion in 2027 as we offset stranded costs. Second, exactly when the Acute Care and Interventional Urology strategic divestiture closes will determine how quickly we can put more capital to work for the rest of 2026. Third, our 2026 adjusted gross margin assumption includes no benefit from IEEPA tariff refunds. Looking ahead to 2027 and past that, we expect our capital deployment moves, together with the effects of the TS and MS agreements and our work to further offset stranded costs and resize the organization, to produce a sizable rise in our adjusted operating income, adjusted margins and adjusted EPS. Now an update on our 2026 guidance. Keep in mind our 2026 guidance is on a continuing operations basis and leaves out the Acute Care, Interventional Urology and OEM businesses; we now expect pro forma adjusted constant currency revenue growth for 2026 in a range of 3.5% to 4.5%, versus 4.5% to 5.5% before. The revised guidance mirrors first-half 2026 performance, a longer time line for integrating the Interventional business, and what we expect from the Vascular and Surgical business in the second half of the year. On adjusted earnings per share, we now expect a higher range of $6.90 to $7.20 in 2026, against our earlier guidance of $6.25 to $6.55. The second quarter's results are part of what our guidance reflects, along with our revised projections for the latter half of 20 that incorporate the gain from share buybacks done in Q2 and reduced net interest expense. No benefit from the proceeds tied to the strategic divestiture of Acute Care and Interventional Urology, nor the expected favorable effect of further repurchases during the back half of 2026 — among them the $250 million ASR I mentioned earlier — is baked into our adjusted EPS guidance. And to remove any ambiguity, no assumption of tariff refund benefits is made in that adjusted EPS guidance right now. Only once the U.S. government gives full confirmation will we recognize the tariff refund. In 2027 and beyond, we anticipate these moves will produce a meaningfully lower share count along with significantly reduced interest expense. All told, we expect buyback activity and balance sheet deleveraging to drive significantly higher adjusted EPS starting in 2027. On top of that, here are items to factor in when modeling: foreign exchange's effect for 2026 remains anticipated at roughly a $14 million tailwind to our pro forma adjusted constant currency revenue growth; our 2026 adjusted operating margin is still expected at approximately 19%. As covered before, once standard costs are addressed, we believe our steady-state margin profile lands at approximately 23%. Going forward, we see room to enhance that steady-state operating margin via operating leverage tied to revenue growth and other cost-saving initiatives. Turning to below-the-line assumptions. For net interest expense, full year 2026 is now expected at approximately $85 million, versus the approximately $105 million assumption we had previously. This revised outlook mainly captures the $700 million debt reduction from our recently completed OEM strategic divestiture close, plus chances to optimize near-term borrowings. Our adjusted tax rate for 2026 is now expected at approximately 12.25%, versus approximately 13.5% before. Last, shares outstanding should approximate $43.3 million, which leaves out any benefit from the announced $250 million ASR. That wraps up my prepared remarks. I'd like to hand the call back to Jason now for closing commentary.
Jason Weidman
executiveThank you, John. To wrap up, I want to emphasize 3 main points from Q2 of 2026. To begin, Teleflex posted a strong second quarter, with revenue, adjusted margins, and adjusted EPS all coming in ahead of expectations. For the latter half of 2026, we anticipate continued solid results in Vascular and Surgical, though growth will be more moderate compared with the first half, along with longer timelines for full Interventional integration. In light of these factors, we've lowered our pro forma adjusted constant currency revenue growth guidance, with the bottom end of that range assuming no gain in Interventional revenues relative to the second quarter for the rest of the year, plus the usual third quarter seasonality. Next, we remain dedicated to giving substantial capital back to shareholders. The accelerated share repurchase and debt paydown during the first half are pushing up our adjusted earnings per share guidance. Our recently closed OEM strategic divestiture will support further buybacks and debt reduction moving forward. Finally, we keep making good progress on our transformation into a leaner portfolio, setting us up for faster growth in 2027 and beyond. We anticipate significant gains in adjusted operating margin and adjusted earnings per share in 2027. On top of that, recent encouraging innovation milestones with EZPlaz and Freesolve underscore our sharper focus on future growth opportunities. That wraps up my prepared remarks. I'd now like to hand the call back to the operator for Q&A.
Vik Chopra
analystI've got two...
Jayson Bedford
analystLet's start with Jason, maybe. Jason, you're stepping into a scenario where the strategy involving transformative deals is mostly in place. Is there anything within that strategy that gives you pause? And could you identify any opportunity areas that perhaps weren't apparent when you took on this role?
Jason Weidman
executiveYeah. Jayson, I appreciate the question. Honestly, one thing that truly — that genuinely drew me toward Teleflex while I was evaluating it from the outside was that transformational strategy. In my view, it was the correct way to bring sharper focus to the business. And now that I've joined, my confidence in that strategy hasn't wavered. Nothing has stood out across these first 2 months that would suggest we're headed down the wrong road. Clearly, we still have to figure out what the long-term direction looks like past that point. So I'm currently in the midst of what I'd describe as my thorough evaluation of the whole organization. And in the months ahead, we'll build the long-term operational and strategic plan aimed at truly delivering long-term durable growth and shareholder value.
Jayson Bedford
analystAll right. Then for my follow-up, perhaps you could go into more depth regarding the VI integration problems — what exactly is going wrong? And what will it take to get the business fully integrated?
Jason Weidman
executiveYeah. That's a good question. The main point I'd like to stress is that this has nothing at all to do with the product. When these 2 portfolios came together — the legacy Teleflex Interventional portfolio and the BIOTRONIK VI portfolio — they complement one another extremely well. I believe all of you are aware that I've been in the Interventional business for the past 20 years. That means I understand this space thoroughly. What I can share is that upon stepping into this role, I received a huge volume of messages — texts and e-mails — from KOLs in the field, and they essentially told me, "You've got a fantastic bag, and we can't wait to see what you accomplish with it at Teleflex." So the product is not the problem. It comes down purely to integration transitions that are still ongoing and temporary, which we have to get through. I'd point mainly to 3 areas. The first is order to cash transitions. The second is distributor transitions. The third is sales force transitions. Every one of these can be handled. Let me begin with more specifics on the OTC side. Whenever you switch a customer's ordering system, regardless of how seamless your internal transfer is — and ours was seamless — it still represents a change for that customer. That creates a chance for disruption and confusion on their end. That's exactly the situation we're in now. We've pinpointed where customer confusion exists along with any remaining issues, and we're methodically resolving them one by one. What I can share is that the bulk of our OTC transitions took place in Q2. That gives us a clear view of how to resolve any customer confusion still lingering. The second area concerns distributor transitions. Whenever you shift from one distributor to another, a timing problem frequently arises. Your previous distributors begin drawing down their inventory, so they cease purchasing, while you have not yet reached the stage of rebuys or initial orders from your new distributors. Clearly, we are monitoring all those distributor-to-distributor transitions carefully and ensuring we push them through to completion. The last area concerns sales force transitions. When 2 sales forces are combined, some territory realignment is inevitably required. As a result, certain reps wind up with new customers. Certain reps wind up with new products to sell. And in certain instances, we discovered that we lacked the appropriate reps to sell this combined bag. Consequently, we have unfilled positions. So we've put together a thorough plan that covers better training and a well-defined roadmap for bringing people on board, and we're already seeing solid movement on that hiring roadmap. So once more, I'd characterize each of these as short-term challenges tied to the integration. On top of that, we've got an incredibly solid base built on truly excellent products. And believe me, I wouldn't have taken this role if I didn't see a major opportunity within the Interventional business.
Vik Chopra
analystJason, roughly 2 months have passed since you started evaluating the company. How soon do you think you'll be able to share what comes out of your strategic review? Also, ought we to put money in — meaning, is a formal long-range plan something we should anticipate? Then I have one brief follow-up, if you don't mind.
Jason Weidman
executiveSure. Appreciate that, Vik. As I mentioned a couple of minutes back, fully assessing the business and assembling that long-range plan ranks among my top priorities. Keep in mind I'm just 2 months into this, so a bit more time is needed. My expectation is that by the next earnings call, I'll be able to offer additional detail and more color regarding where I think the company should head.
Vik Chopra
analystAll right, that's helpful. Now a brief follow-up regarding BIOTRONIK. What I'd like to know is how confident you are that the timeline we have right now captures the entire scope of the hold-up?
Jason Weidman
executiveYes, yes. As I mentioned, the primary drivers behind the integration delay — we've got mitigations set up for those, and progress is already showing across each of those areas. So our confidence is fairly strong, or actually quite strong, that we ought to be able to resolve this before the year is out. And because of that, our guidance takes that into account as well.
Analyst
analystGreat. Two fast items to kick things off. Looking at the company and thinking it through, I realize you've only had a few months in the role, but the guidance seems to point toward a somewhat more cautious back half for evesa — something like 3% or a bit above, as I understand it. Is there any reason you'd see that over the medium term, this shouldn't be a business capable of roughly 4% growth? Is there something we could be overlooking, maybe the procedure environment or something along those lines, that would rule out 4%-plus as a sensible medium-term yardstick?
Jason Weidman
executiveYes. Appreciate that, Patrick. Nothing significant comes to mind that you're overlooking. Let me return to the guidance and make it very clear. As we consider this updated adjusted revenue growth outlook of 3.5% to 4.5%, it applies to the whole year and to all of RemainCo. And we won't provide guidance at the individual business level; with that said, the full amount of the decrease versus the prior guidance stems from this integration slowdown in Interventional.
Michael Sarcone
analystMike Sarcone here, filling in for Matt Taylor. I suppose this is a follow-up regarding the guidance. In the prepared commentary, I believe you noted potentially somewhat more moderate growth expectations for the latter half of the year in Vascular and Surgical too. Could you clarify that and expand on it relative to what you said when answering the previous question about your guidance?
Jason Weidman
executiveAbsolutely, happy to. So to repeat, the cut to guidance stems entirely from what we're seeing in Interventional — having said that, we added further detail during the prepared remarks so you'd feel confident about our capacity to reach the bottom end of the range. And here's what that was — the bottom end of the range essentially assumes zero growth for Interventional over the rest of the year. So you take that Q2 revenue figure we posted in Interventional and presume it stays the same for the rest of the year, with merely a bit of extra seasonality in Q3.
Larry Keusch
executiveRegarding our remaining 2 segments, Vascular and Surgical, we anticipate they will keep delivering very strong results; however, they've posted high single-digit expansion during the first half of the year, which is great, yet these aren't markets that grow at a high single-digit pace. Take Vascular, for example: we did observe that with certain key distributors, stock levels edged up somewhat in H1. So eventually, we'd anticipate that situation will return to normal. Turning to Surgical, as we move into the latter half of this year, honestly, we simply encounter harder comparisons. If you examine last year's H2, that's the point when the instrument portfolio began showing some momentum.
Michael Sarcone
analystUnderstood, that's useful. And perhaps just, could you say something about whether you've observed any effect from the expiration of ACA subsidies, and simply, in terms of patient demand as well as utilization?
Jason Weidman
executiveWe have not observed any effect from that.
Jason Bednar
analystI'd like to revisit those 3 buckets you walked through before, the ones affecting the revenue outlook, and dig deeper. When it comes to the first 2, OTC plus the distributor dynamics, from my perspective, they sound fairly manageable and quite controllable. It's that final one, the sales force piece, and I would really like to hear your thinking on it, specifically whether it will be completely resolved by year-end. Since a number of those roles remain unfilled, and in medtech we've all witnessed that ramp-up tends to require a bit of time, given that we're sitting in the middle of the year, I just want your comfort level or confidence about tackling that sales force, Keith.
Jason Weidman
executiveYes. I believe that's an excellent question. I have confidence that we can complete the hiring plan. I have confidence that with the reps we have now, we can complete the enhanced training that must be done. However, as you're aware, in these areas, generally it takes roughly 6 months to bring a rep up to speed. Therefore, my assumption is that our ramp-up will not be a step up but rather a ramp up, precisely what you're describing.
Jason Bednar
analystOkay, that's useful. And I don't want to overlook all the hard work that's happening in 2026 — plenty of us are naturally also focused on where growth is headed for '27 and what EPS looks like for '27. Given margin normalization, capital deployment, and everything else at play, it's easy to imagine EPS reaching something around $11.25 or $11.50 for next year. Jason, I realize you're kind of the first call here. I'd just really like to hear your take on that.
Jason Weidman
executiveWell, listen, I'm going to — I'll hand that over to John to address what our expectations are regarding EPS. But yes. Go ahead, John.
John Deren
executiveClearly, we aren't in a position to provide guidance for 2027 at this point. I value your perspective, and whether your model is right or wrong isn't something I can really say, but what I would say is that considering the 23% operating margin as things stand right now, the figures you've mentioned seem fairly reasonable to me.
Nathan Treybeck
analystNathan Treybeck here, filling in for Larry. Jason, CMS is altering what it requires for NTAP, and having a breakthrough designation from the PPT program no longer removes the obligation to demonstrate a clinical advance in order to get enhanced reimbursement. What does that mean for Freesolve, and what price might you set for it?
Jason Weidman
executiveSure, as you're aware, under those rules, the shortcut was simply removed — previously, if you held breakthrough device designation, you didn't need to prove superiority — so we understand that this is disappearing and that route is closing off. That said, we have many scenarios under consideration for Freesolve over the long term. And of course, we're examining various metrics through which we might also try to demonstrate that this device could potentially offer superiority over the long term. But in any case, this holds true no matter where that NTAP or TPT lands. Our view is that should this pan out clinically in the randomized trials, it represents a great opportunity regardless.
Nathan Treybeck
analystGreat. I'd also like to ask about Orsiro — what share of Interventional revenue does it represent right now? Is it falling at roughly the same pace as the broader DES market? And do you believe you can turn that product's trajectory around?
Jason Weidman
executiveThe first thing I'd say is that we won't provide guidance on specific figures or discuss the growth rates of individual product lines. That's simply not something we do. I can talk about the DES market in general terms, which I'd describe as roughly flat. So pricing typically offsets the PCI expansion occurring around the world. Regarding Osiro, I'd note that its share position is fairly small — not due to any shortcoming as a product, but simply because we haven't had the commercial bandwidth worldwide to truly push it. So I genuinely believe there's a chance for us to beat the market over time with this product. Osiro has been studied in 70,000 patients; it's a solid product. It has amazing data versus Xience, and I'm excited to see what we can do with it.
Mike Matson
analystI'd like to begin with a question regarding EZPlaz. I do appreciate the remarks you made, but I barely heard anything about the market opportunity. In the past, I believe you mentioned this could be roughly a $100 million market within the U.S. And what about when the launch will happen and how sales might ramp up?
Jason Weidman
executiveYes. Excellent question. Let me begin by saying I'm extremely pleased about this landmark approval. It really shows Teleflex's growing dedication to innovation. The company has spent over a decade working on this, and it is definitely not a simple project or a simple innovation. We have now become the first and only freeze-dried plasma licensed by the FDA. I wanted to praise the team for that before getting to your question. Now, regarding EZPlas, what I want to clarify is that our initial and immediate focus is the government and military market within the United States; there is a great deal of work that must be done there; so the following steps involve a procurement solicitation with the Department of War, after that we must negotiate a contract, then sign a contract, and begin actually delivering product commercially; we are currently involved in those discussions and they are progressing well. For 2026, I would expect any revenue from EZPlaz to be immaterial. But during 2027, it will contribute. As for the long-term market, I know that many years ago, the company had characterized this as a $100 million opportunity. As you might expect, being new to the role, I want to reevaluate how we can pursue new segments and what the total market opportunity might be; and I'd say we are still in the midst of that. So I'd say it would be premature for me to comment on the total market opportunity over time.
Mike Matson
analystAll right, I get it. Then, regarding Freesolve and the BIOMAG-2 trial — results from which, as I understand it, you anticipate around late next year — what exactly is riding on that study? So can we safely conclude that positive findings there would let you see sales accelerate considerably more outside the U.S., where the product is already being sold across Europe and elsewhere?
Larry Keusch
executiveYeah. Excellent question. When we consider Freesolve beyond the United States, you've got it exactly right. It isn't an approval matter standing in the way of a sales ramp — the real obstacle is data, or rather insufficient data, plus the guidelines. And so we don't — what we have is genuinely strong single-arm evidence thus far from BIOMAG-1, which in my view is hypothesis generating. Physicians tell us great things, the device behaved comparably to a conventional DES, and outcomes from that single-arm study resemble those of a conventional DES; yet clearly, we must see this confirmed through randomization; therefore, as you mentioned, enrollment in BIOMAG-2 has been completed — roughly 2,000 patients randomized against Xience. That enrollment wrapped up ahead of schedule. Consequently, a readout will come next year. That ought to resolve the data concern; so we're eager for it and to truly learn how this stacks up against DES. And after that — though beyond that point, as I noted, a guidelines concern also exists; specifically the major guidelines outside the U.S., meaning in cardiology, or the ESC guidelines, the European Society of Cardiology Guidelines. At present, those guidelines say bioabsorbable scaffolds ought to be used solely within a clinical trial setting. So even once we obtain knock on wood positive data next year, we'll still need to engage with ESC to ensure those guidelines are revised, though positive data ought to make that possible.
Anthony Petrone
analystWelcome aboard, Jason. It's a pleasure to connect with you by phone, and I hope things are going well for you, John. I've got one question about procedure volumes — a broader one — plus one about capital allocation. Any of the 3 segments can serve as a proxy for procedure volumes. Vascular organic sits at 8%, your surgical is <<inaudible>>, and clearly with Interventional, organic growth is down 1%. How much can you share with us regarding U.S. procedure volumes? There's been a fair amount of noise out there. HCA reported inpatient admissions lower, and some med tech companies aren't experiencing any effects, while others are. So from the Teleflex standpoint, how do you see U.S. procedure volumes shaping up as we head into the back half of the year? Then I'll ask a follow-up about capital.
John Deren
executiveYes, certainly. So, in brief, it's much like what I mentioned earlier: we truly aren't observing any effect on procedure volumes. In our view, that isn't the force behind how our businesses have been performing.
Anthony Petrone
analystAnd turning to how we're deploying capital — that $250 million ASR. My understanding is the earlier goal was $1 billion in total. So following the OEM divestiture, you executed a $250 million initial buyback as an ASR rather than retiring debt. Could you just walk back through the capital allocation picture — what's the ongoing mix between repurchasing shares and servicing debt? And naturally, M&A has always been in Teleflex's DNA. Jason, what's your thinking there?
Jason Weidman
executiveYeah, absolutely. Broadly speaking, our commitment to the $1 billion share repurchase and the $800 million in debt reduction hasn't changed. As you mentioned, we finished the $250 million buyback during Q2. That was the first $250 million, and we've now announced the following $250 million ASR, which begins tomorrow. The other $500 million will probably come from the money raised in the Acute Care and Interventional Urology divestiture, once that transaction closes. On lowering debt, we used the OEM proceeds to pay down $700 million — that was debt tied to the BIOTRONIK acquisition — and later we'll retire the extra $100 million we pledged before this year ends. Regarding your acquisition question, the first thing I'd note is that we currently have a great deal on our plate that must be executed, and that's where our attention sits. We have to ensure both divestitures are completed; we have to ensure BIOTRONIK is fully integrated, and then we'll take it from there. Still, my general philosophy on acquisitions is that anything we'd consider would have to be a tuck-in for the businesses we'll have in RemainCo. At least over the short to midterm, I have no interest in anything transformational.
Ravi Misra
analystI'd also like to pass along my congratulations, and it's great to begin collaborating with you, Jason, across the next several quarters. I suppose I have two questions, and I'll just ask them right away. Could you perhaps share a bit about Pantera Lux — what exactly is happening in the DCBISR space? A competitor of yours has been posting really explosive growth in that area. So I'd simply like to grasp how you see the opportunity there. Then, secondly, regarding the vascular momentum, there's an acceleration in growth even with a few of those supplier challenges you brought up. You discussed ordering patterns somewhat. Could you perhaps show us, John, what a stabilized end market for this segment would resemble?
Jason Weidman
executiveStarting with your first question about DCB. Yes, DCB has indeed represented a terrific growth opportunity, especially within the coronary space across the past two years. Within our Interventional business, we view this as a growth segment, and we see additional opportunity globally; we're examining various options for bringing our DCs into the United States and into Japan, though because of certain contractual items tied to these products, the Lux platform, it isn't exactly simple; so we're continuing to figure out what our various options might be. Let's see. Then the other question concerned the Vascular segment, and yes, ordering patterns and where we observed the market stabilizing. So, once more, we had a really strong business, in terms of our performance in our Vascular business during H1; especially in the second quarter, I want to highlight that our team did a wonderful job handling the Lidocaine recall, which we believed might have hurt us during the quarter with a back order, yet our team truly, truly worked through it well. As I said earlier, though, when we monitor the inventories at the major distributors, they've edged up somewhat. And so we'd anticipate them to settle down a bit toward the back end. Ultimately, this is a mid-single-digit growth market.
Mike Polark
analystTo follow up regarding the BIOTRONIK integration update, I'm just wondering about the revenue side, or what you might call the disruption side. Does that involve legacy BIOTRONIK, or does it involve legacy Teleflex, or do both play a role? And is there a particular geographic region that stands out more — Europe or the U.S.?
Jason Weidman
executiveWell, we don't provide specifics at the product line level, but I believe it's fair to state that the revenue base from the legacy — or the BIOTRONIK BI acquisition — was affected disproportionately by the difficulties encountered during integration.
Mike Polark
analystThen a question about tariff refunds. John, I heard you say these weren't received and aren't included in the guidance — that's useful. Some companies are reporting that they got refunds like these during the second quarter; so why haven't you seen any? Are you expecting them to arrive in the third quarter? Could you help us understand how you'd account for them should they eventually show up?
John Deren
executiveYes; we did have some refunds this quarter, though they weren't — they were somewhat divided between RemainCo and NewCo, meaning between DO and CO. They also pertained to 2025. Our non-GAAP policy means we recognize only items tied to 2026 into earnings. That said, the sole chance for 2026 refunds is roughly $15 million that landed in Q1 and Q2; so once those refunds do arrive, that sum would return into earnings. Timing is hard for me to address since it's somewhat uncertain. All the refunds have been submitted by us, but that money will return into earnings, that $15 million. At present, altogether, we anticipate roughly $39 million in cash refunds to Teleflex.
Travis Steed
analystSince you're stepping in as the new CEO, I would really like to hear your take on what creating value for shareholders means to you. There's plenty of strategic and financial activity happening across med tech, whether through standalone approaches or other routes. But given that you're arriving fresh and this is clearly a new chapter — a sort of new path year for Teleflex — I'd just love for you to share a bit about your own thinking, especially regarding how shareholder value gets created.
Jason Weidman
executiveSure. Appreciate that, Travis. At this moment, there's a great deal for me to absorb in both this role and this company. So my focus has genuinely been on picking up as much as possible. As I mentioned, my priorities have centered on understanding deeply — on zeroing in on carrying out those major items we need to advance: the divestitures, the integration, and so forth — and then on building out that strategic plan for what lies ahead over the long term. So once more, I stay dedicated to the framework Teleflex has already established, including the share repurchase and the debt paydown. I also feel strongly about innovation and have faith that organic R&D fuels shareholder value. If you consider what we've accomplished at Teleflex during the first half, R&D is approaching 8% of revenue, compared with the 6% we saw at historical levels. Yet when I think about precisely how I wish to handle capital allocation and any long-term shifts past that point, I would request that you allow me a bit more time — I want the chance to thoroughly evaluate every part of the business before anything else.
Larry Keusch
executiveMuch appreciated, JL, and I want to thank each of you for being with us on today's call; that brings the Teleflex Inc. Second Quarter 2026 Earnings Conference Call to a close.
Operator
operatorYou may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.